

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
WORKING PROCEDURES	7
A. GENERAL PRINCIPLES AND PROCEDURES	7
1. Background	7
2. Objective and scope	7
3. Selection of interventions for review	8
4. Data for the <i>IARC Handbooks</i>	8
5. Meeting participants	9
B. SCIENTIFIC REVIEW AND EVALUATION	10
1. Characteristics and occurrence of the intervention.....	11
2. Studies of cancer prevention in humans.....	11
3. Studies of cancer prevention in experimental animals	13
4. Mechanistic and other relevant data	15
5. Summary of data	17
6. Evaluation and rationale	17
References	20
GENERAL REMARKS	21
LIST OF ABBREVIATIONS	25
1. BODY FATNESS	29
1.1 Background and definitions.....	29
1.1.1 Scientific definitions of obesity.....	29
1.1.2 Cultural definitions of obesity.....	29
1.1.3 Body fatness as a public health problem	30
1.2 Prevalence and trends	30
1.2.1 Prevalence and trends in adults.....	30
1.2.2 Prevalence and trends in children and adolescents.....	31
1.2.3 Prevalence by age and sex	34
1.2.4 Prevalence by ethnicity	35
1.2.5 Prevalence by social class and education.....	36

1.3	Risk factors.....	37
1.3.1	Regulation of hunger and satiety.....	37
1.3.2	Weight gain throughout the life-course.....	38
1.3.3	Excessive energy intake.....	40
1.3.4	Endocrine disruptors.....	42
1.3.5	Physical activity and sedentary behaviour.....	44
1.3.6	Built environment.....	45
1.3.7	Social determinants.....	47
1.3.8	Microbiota and gastrointestinal environment.....	48
1.3.9	Genetic and epigenetic determinants of body fatness.....	49
1.4	Assessment of anthropometric measures and body composition.....	50
1.4.1	Weight and height.....	50
1.4.2	Indexes of adiposity.....	51
1.4.3	Other measures of adiposity or body composition.....	53
1.4.4	Change in weight.....	55
1.4.5	Assessment of paediatric adiposity.....	56
	References.....	56
2.	CANCER-PREVENTIVE EFFECTS IN HUMANS.....	71
2.1	Methodological considerations.....	71
2.1.1	Bias.....	71
2.1.2	Confounding.....	72
2.1.3	Reverse causation.....	72
2.1.4	Mendelian randomization.....	73
	References.....	73
2.2	Cancer-preventive effects by organ site.....	74
2.2.1	Cancer of the colorectum.....	74
	References.....	109
2.2.2	Cancer of the oesophagus.....	113
	References.....	132
2.2.3	Cancer of the stomach.....	134
	References.....	161
2.2.4	Cancer of the liver (hepatocellular carcinoma).....	164
	References.....	180
2.2.5	Cancer of the gall bladder.....	182
	References.....	192
2.2.6	Cancers of the biliary tract.....	194
	References.....	195
2.2.7	Cancer of the pancreas.....	196
	References.....	227
2.2.8	Cancer of the lung.....	231
	References.....	233
2.2.9	Cancer of the breast in women.....	235
	References.....	283
2.2.10	Cancer of the breast in men.....	290
	Reference.....	290

2.2.11 Cancer of the endometrium	291
References	307
2.2.12 Cancer of the cervix	311
References	311
2.2.13 Cancer of the ovary	313
References	333
2.2.14 Cancer of the prostate	336
References	375
2.2.15 Cancer of the testis	380
References	381
2.2.16 Cancer of the kidney (renal cell carcinoma)	382
References	396
2.2.17 Cancer of the urinary bladder	398
References	399
2.2.18 Primary tumours of the brain and central nervous system	401
References	410
2.2.19 Cancer of the thyroid	411
References	420
2.2.20 Haematopoietic malignancies of lymphoid origin	422
References	450
2.2.21 Other haematopoietic malignancies	453
References	454
2.2.22 Cancers of the head and neck	456
References	459
2.2.23 Malignant melanoma	461
References	462
2.3. Excess body fatness in early life and subsequent cancer risk	463
2.3.1 Weight and height measured in childhood	463
2.3.2 Body shape in early adulthood determined by recall	464
2.3.3 Trajectories of body shape determined from early life	465
References	475
2.4 Excess body fatness in cancer survivors	477
2.4.1 Studies of weight at diagnosis and cancer outcomes	477
2.4.2 Studies of weight change after cancer diagnosis and cancer outcomes	478
2.4.3 Intervention trials of weight-loss intervention and dietary modification	478
References	479
2.5 Sustained weight loss and cancer risk: illustrative examples	481
2.5.1 Studies of weight loss and cancer risk	481
2.5.2 Studies of bariatric surgery and cancer risk	481
References	485
3. CANCER-PREVENTIVE EFFECTS IN EXPERIMENTAL ANIMALS	487
3.1 Methodological considerations	487
3.1.1 Definition of dietary/calorie restriction	487
3.1.2 Design issues in studies of dietary restriction	487
3.2 Overview of the effects of excess body weight	489

3.2.1	Obesity models	489
3.2.2	Cancer of the mammary gland	490
3.2.3	Cancer of the colon	493
3.2.4	Cancer of the liver	494
3.2.5	Cancer of the prostate	495
3.2.6	Cancer of the skin (melanoma)	497
3.2.7	Cancer of the pancreas	498
3.2.8	Cancer of the endometrium of the uterus	499
3.2.9	Leukaemia	499
3.3	Preventive effects of dietary/calorie restriction	500
3.3.1	Cancer of the mammary gland	500
3.3.2	Cancer of the colon	514
3.3.3	Cancer of the liver	518
3.3.4	Cancer of the pancreas	522
3.3.5	Cancer of the skin and subcutaneous tissue	526
3.3.6	Cancer of the pituitary gland	531
3.3.7	Cancer of the prostate	537
3.3.8	Cancers of the haematopoietic system	537
	References	545
4.	MECHANISTIC AND OTHER RELEVANT DATA	553
4.1	Introduction	553
4.2	Intracellular factors	554
4.2.1	Cell proliferation, apoptosis, and angiogenesis	554
4.2.2	The mTOR network and other energy-sensor networks	557
4.2.3	Epigenetics, oxidative stress, DNA repair, and telomeres	559
4.3	Receptor-mediated effects	564
4.3.1	Sex hormones	564
4.3.2	Insulin resistance	567
4.3.3	Insulin-like growth factors	570
4.3.4	Chronic inflammation	571
4.3.5	Vitamin D	577
4.3.6	Other factors	579
	References	611
5.	SUMMARY OF DATA	633
5.1	Exposure data	633
5.2	Cancer-preventive effects in humans	634
5.2.1	Cancer of the colorectum	634
5.2.2	Cancer of the oesophagus	635
5.2.3	Cancer of the stomach	635
5.2.4	Cancer of the liver (hepatocellular carcinoma)	635
5.2.5	Cancer of the gall bladder	635
5.2.6	Cancers of the biliary tract	636
5.2.7	Cancer of the pancreas	636
5.2.8	Cancer of the lung	636

5.2.9	Cancer of the breast in women	636
5.2.10	Cancer of the breast in men	636
5.2.11	Cancer of the endometrium	636
5.2.12	Cancer of the cervix	637
5.2.13	Cancer of the ovary	637
5.2.14	Cancer of the prostate	637
5.2.15	Cancer of the testis	637
5.2.16	Cancer of the kidney (renal cell carcinoma)	637
5.2.17	Cancer of the urinary bladder	637
5.2.18	Primary tumours of the brain and central nervous system	638
5.2.19	Cancer of the thyroid	638
5.2.20	Tumours of the haematopoietic system	638
5.2.21	Cancers of the head and neck	638
5.2.22	Malignant melanoma	639
5.2.23	Excess body fatness in early life and subsequent cancer risk	639
5.2.24	Excess body fatness in cancer survivors	639
5.2.25	Sustained weight loss and cancer risk	639
5.3	Cancer-preventive effects in experimental animals	639
5.3.1	Excess body weight	639
5.3.2	Dietary/calorie restriction	640
5.4	Mechanistic and other relevant data	643
5.4.1	Sex hormone metabolism	643
5.4.2	Inflammation	643
5.4.3	Insulin and insulin-like growth factor	644
5.4.4	Epigenetic alterations	644
5.4.5	Oxidative stress	644
5.4.6	DNA repair	644
5.4.7	Telomeres	644
5.4.8	Other mechanisms	644
6. EVALUATION		645
6.1	Cancer-preventive effects in humans	645
6.2	Cancer-preventive effects in experimental animals	645
6.3	Mechanistic and other relevant data	645
6.4	Overall evaluation	645